Bladder transitional cell carcinoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:26 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Bladder transitional cell carcinoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on IO102-IO103 and Pembrolizumab for Patients with Metastatic Lung, Head and Neck, or Bladder Cancer https://clinicaltrials.eu/trial/study-on-io102-io103-and-pembrolizumab-for-patients-with-metastatic-lung-head-and-neck-or-bladder-cancer/ Wed, 29 Apr 2026 14:57:06 +0000 https://clinicaltrials.eu/trial/study-on-io102-io103-and-pembrolizumab-for-patients-with-metastatic-lung-head-and-neck-or-bladder-cancer/ This clinical trial is focused on studying the effectiveness and safety of a new treatment combination for certain types of cancer. The diseases being studied are Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), and Metastatic Urothelial Bladder Cancer (mUBC). The treatment being tested combines two medications: IO102-IO103 and Pembrolizumab, which is also known by its brand name, Keytruda. IO102-IO103 is a type of protein-based treatment, and Pembrolizumab is a medication that helps the immune system fight cancer.

The purpose of this study is to see how well this combination works as a first-line treatment, meaning it is the first treatment given for these cancers. The study will involve patients receiving the treatment through injections. IO102-IO103 is given as a subcutaneous injection, which means it is injected under the skin, while Pembrolizumab is given as an intravenous infusion, meaning it is delivered directly into a vein. The study will last for up to 24 months, during which the safety and effectiveness of the treatment will be closely monitored.

Participants in the study will be those who have not received prior systemic treatment for their metastatic disease. The study aims to determine if this combination can provide a significant clinical benefit for patients with these specific types of cancer. The trial will also assess various outcomes, such as how long patients live without the disease getting worse and the overall response to the treatment. The results will help in understanding if this combination can be a viable treatment option for these cancers.

]]> Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-xl092-with-nivolumab-ipilimumab-and-relatlimab-for-patients-with-advanced-solid-tumors/ Wed, 29 Apr 2026 14:30:37 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-xl092-with-nivolumab-ipilimumab-and-relatlimab-for-patients-with-advanced-solid-tumors/ This clinical trial is focused on studying the effects of a new treatment for various types of advanced or metastatic solid tumors, which are cancers that have spread to other parts of the body and cannot be removed by surgery. The diseases being studied include clear cell renal cell carcinoma, metastatic castration-resistant prostate cancer, urothelial carcinoma, non-clear cell renal cell carcinoma, colorectal cancer, hepatocellular cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma. The study will test a combination of medications, including zanzalintinib, nivolumab, ipilimumab, and relatlimab. These medications are designed to work together to help the immune system fight cancer.

The purpose of the study is to find the best dose of these medications and to see how safe and effective they are when used together. Participants will receive the medications in different combinations, either as a single treatment or in pairs or triplets. The study will also look at how the body processes these medications and how they affect cancer cells. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

During the study, participants will receive the treatment over a period of time, and their health will be closely monitored by the research team. The study will help determine the safety and potential benefits of these treatments for people with advanced cancers. The information gathered will contribute to understanding how these medications can be used to treat different types of cancer effectively.

]]> Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-solid-tumors-who-have-not-received-immunotherapy/ Wed, 29 Apr 2026 14:27:04 +0000 https://clinicaltrials.eu/trial/study-of-incb099280-for-patients-with-advanced-solid-tumors-who-have-not-received-immunotherapy/ This clinical trial is focused on studying the effects of a new treatment called INCB099280 on certain types of cancer known as solid tumors. These tumors are advanced or have come back after treatment, and the patients have not previously received a type of treatment called immunotherapy. The purpose of the study is to understand how safe and tolerable the treatment is, and to see how well it works in managing these tumors.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.

]]>